Lilly reports positive psoriatic arthritis study data for Taltz

Lilly has announced new clinical trial data that demonstrates the safety and efficacy of its drug Taltz in the treatment of psoriatic arthritis.

The company has shared findings from the SPIRIT-P1 phase III trial at the Annual European Congress of Rheumatology, showing that the majority of patients with active psoriatic arthritis treated with Taltz exhibited minimal or no progression of radiographic structural joint damage over 52 weeks of treatment.

Meanwhile, results from the SPIRIT-P2 study were also shared at the conference, demonstrating that Taltz delivered significant improvements in signs and symptoms of disease at 24 weeks among patients who were unable to benefit from treatment with anti-TNF therapies.

Psoriatic arthritis is a chronic, progressive disease that affects more than 37 million people worldwide, and the availability of Taltz offers a new therapeutic option to address unmet medical needs among this demographic.

Dr Lotus Mallbris, global brand development leader for Taltz at Lilly, said: "For patients living with psoriatic arthritis, it is important to work with a specialist to find a treatment that manages both the signs and symptoms of the disease, but also helps prevent further joint damage."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.